Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
Abbisko HK$1.7 billion IPO
We advised Abbisko on its IPO and HKEX listing
PHC Holdings ¥82.6 billion IPO
We advised the international managers in connection with the IPO and TSE listing
Supernus Pharmaceuticals $450 million acquisition of Adamas Pharmaceuticals
We are advising Lazard as financial adviser to Adamas
Securities litigation victory for Synergy Pharmaceuticals officers and directors
We secured a total victory for the clients, with all claims against them dismissed
Inventiva at-the-market offering
We advised the sales agent on the SEC-registered offering of ADSs
Broncus Holding HK$1.55 billion IPO
We advised Broncus on its IPO and HKEX listing
Eli Lilly €1.8 billion and £250 million notes offering
The investment-grade offering included the company’s inaugural sustainability bonds
Maravai LifeSciences $1 billion secondary offering
The shares are listed on the Nasdaq Global Select Market
PerkinElmer $2.3 billion senior notes offering
We advised the underwriters on the investment-grade debt offering
MultiPlan $1.05 billion notes offering and $1.775 billion credit facility
We advised the initial purchasers on the secured high-yield debt offering and the lead arrangers on the new credit agreement